drug
(glimepiride + pioglitazone hydrochloride)
Marketedupdated 3mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 30, 2027
169 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jun 8, 2028formulationUS 80711301.8y
- Jun 8, 2028formulationUS 80711301.8y
- Jan 30, 2027formulationUS 7700128169d
- Jan 30, 2027formulationUS 7700128169d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that